An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.

On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

The stroma to tumor ratio potentially identifies higher risk bladder cancer tumors and might help guide immunotherapy. Bladder tumors with higher stromal content may have a more immunosuppressive ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United States. Despite recent advances, the 5-year survival rate for metastatic UC ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC ...